A Phase I Trial of Vorinostat and Bortezomib in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Study (ADVL0916)

BACKGROUND: A pediatric phase I trial was performed to determine the maximum tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE: Oral vorinostat was administered on days 1–5 and 8–12 of a 21 day cycle (sta...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Muscal, Jodi A., Thompson, Patrick A., Horton, Terzah M., Ingle, Ashish M., Ahern, Charlotte H., McGovern, Renee M., Reid, Joel M., Ames, Matthew M., Espinoza-Delgado, Igor, Weigel, Brenda J., Blaney, Susan M.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3511610/
https://ncbi.nlm.nih.gov/pubmed/22887890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24271
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars